Viewing Study NCT06012435

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:02 PM
Ignite Modification Date: 2026-03-05 @ 1:33 AM
Study NCT ID: NCT06012435
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-15
First Post: 2023-08-21
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma, Non-Small-Cell Lung View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Non-Small Lung Cancer View
None Seattle Genetics View
None lung cancer View
None advanced lung cancer View
None metastatic lung cancer View
None non small cell lung cancer View
None stage 3 lung cancer View
None stage 4 lung cancer View
None lung cancer treatment View
None lung cancer clinical trial View
None nonsquamous lung cancer View
None ADC View
None Pfizer cancer trial View
None vedotin View
None lung disease View
None phase 3 lung View